{
  "id": 9157931,
  "title": "Gold nanoplasmonic chip tracks L-DOPA response in Parkinson's 'mini-brains'",
  "url": "https://urgent.news/2026/09/22/gold-nanoplasmonic-chip-tracks-l-dopa-response-in-parkinsons-mini",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-22T16:00:04.000Z",
  "source": {
    "name": "Phys.org",
    "slug": "phys-org",
    "url": "https://phys.org/news/2026-09-gold-nanoplasmonic-chip-tracks-dopa.html"
  },
  "original_language": "en",
  "account": "Researchers have created an organoid-on-a-chip technology that can monitor the effectiveness of Parkinson's disease treatments in real time. The technology consists of a mini-brain derived from stem cells and a nanoplasmonic sensor that maximizes light-matter interaction. The mini-brain, modeled after the brainstem, closely resembles an actual organ. Parkinson's disease is a neurodegenerative disorder caused by damage to dopamine-secreting cells, leading to tremors and muscle rigidity. Traditional drug research methods involve destroying cells or using staining techniques, making it challenging to track drug efficacy in living tissue. The researchers overcame this limitation by using a gold nanoplasmonic sensor with an aptamer that responds specifically to dopamine. This allowed for highly precise detection of secreted dopamine levels without harming the mini-brain tissue. By delivering culture medium and drugs through microscale channels in a microfluidic chip environment, the team measured the response of Parkinson's brainstem organoids in real-time over 12 hours. The results provided detailed information about the recovery of dopamine secretion after administering the Parkinson's treatment L-DOPA. Importantly, the study also confirmed that increasing drug concentration does not always improve therapeutic outcomes, successfully identifying the optimal dosage that is both safe and effective for patients. This achievement demonstrates the ability to precisely measure the timing of drug onset, peak effect, and duration of action in a model that mimics human brain tissue. This technology is expected to significantly reduce the gap between animal testing and human clinical trials, ultimately shortening drug development timelines. The research team, led by Inki Kim from Sungkyunkwan University, envisions further development of this technology as a core platform for patient-specific drug development and disease treatment.",
  "summary": "Researchers have developed an organoid-on-a-chip technology that verifies the efficacy of Parkinson's disease treatments in real time. The technology combines a stem cell–derived \"mini-brain\" with a nanoplasmonic sensor engineered to maximize light–matter interaction.",
  "key_points": [
    "Researchers developed organoid-on-a-chip technology to monitor Parkinson's treatments in real-time.",
    "Gold nanoplasmonic sensor with aptamer detects dopamine levels without harming mini-brain tissue.",
    "Study identified optimal L-DOPA dosage, reducing gap between animal testing and human trials."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}